Biography
3 months living and learning in Kisumu in 2012, a small village in the South of Kenya, has significantly changed my perspectives about life and health. My passion for Tuberculosis has gained since then and I was lucky enough to do what I love until now. As a DRTB program officer, I'm in charge of planning, drugs forecasting, monitoring and evaluation, technical assistance, training … related to drug resistant TB program in Vietnam. It’s such an inspiring work as more and more DRTB patients, who are poor and hopeless, are treated and cured because of what we’re doing.
Key Impacts
Post-treatment outcomes three years after a 9-month regimen for rifampicin-resistant TB in Vietnam
The study result showed high and sustained treatment success rate of 9-11-month BCLLfxZ regimen from endTB trial. Given that 6-month regimen including new drug pretomanid is not yet available in many settings, BCLLfxZ is a robust alternative for fluoroquinolone-susceptible RR-TB treatment.
Source: Conference 2024
Treatment outcomes of rifampicin-resistant TB under programmatic conditions in Vietnam in 2021 - 2022
During the transition from long to short regimens, nationwide data showed 71.2% RR-TB treatment success in Vietnam. The wider use of short regimens and addressing LTFU can improve outcomes. More robust and better managed long regimens are needed for those not eligible for any STR.
Source: Conference 2024